Lotte Biologics Targets Global Expansion at DCAT Week 2026
Industry Insights from Next Move Strategy Consulting
Lotte Biologics is set to participate in DCAT Week 2026, a premier gathering of the pharmaceutical and biotechnology sectors in New York from March 23 to 26, signaling the company’s push to expand global partnerships and reinforce its presence in the contract development and manufacturing organization (CDMO) market.
Strengthening Global Footprint Through Strategic Engagement
At DCAT Week, Lotte Biologics will host meetings at the Lotte New York Palace, engaging with potential partners and exploring business opportunities, particularly in North America. The company plans to showcase the synergy between its Syracuse Bio Campus in New York and the upcoming Songdo Bio Campus in Incheon, scheduled for completion in August. This dual-site model is designed to offer global clients more flexible and reliable manufacturing capabilities, reflecting a strategic commitment to operational excellence across regions.
“Our participation at DCAT Week allows us to connect with industry leaders and identify opportunities to grow our partnerships,” the company said.
Expanding Services Through Collaboration
Lotte Biologics will also highlight the expansion of its service portfolio through strategic alliances. Notably, its collaboration with US-based cell line development specialist Asimov enables comprehensive “DNA-to-drug-substance” services. This integrated approach reduces the development timeline to approximately 8.5 months from transfection to drug substance release, demonstrating efficiency gains and streamlined manufacturing processes.
According to Next Move Strategy Consulting
Lotte Biologics’ approach of leveraging dual manufacturing sites across the US and South Korea, combined with strategic collaborations, is likely to enhance its competitiveness in the global CDMO market. This strategy not only provides clients with faster and more reliable development timelines but also positions Lotte Biologics as a stronger partner for pharmaceutical companies seeking integrated solutions.
By participating in DCAT Week, Lotte Biologics reinforces its ambition to expand international partnerships and strengthen its position as a key player in the global biologics manufacturing landscape.
Source: Lotte Biologics
Prepared by: Next Move Strategy Consulting
About the Author
Joydeep Dey is a content writer and analyst fueled by creativity, research, and continuous learning. He combines compelling storytelling with market insights to turn complex information into engaging, impactful content. Passionate about emerging trends, digital strategy, and innovation-driven communication, he believes curiosity and consistent growth are key to creating meaningful influence in every project.
About the Reviewer
Sanyukta Deb is a senior content writer and content analyst with expertise in content strategy, audience engagement, and research-driven storytelling. With a strong leadership approach and strategic mindset, she drives content initiatives that strengthen brand communication and audience connection. She combines creativity with analytical insight to develop impactful, value-led content while mentoring collaborative efforts across teams to ensure consistent, meaningful engagement and long-term brand growth across digital platforms.
Add Comment